EIF2AK3 Protein (PERK)

📖 Wiki Page

protein1678 wordssynced 2026-04-02

EIF2AK3 Protein (PERK)

Introduction

...

EIF2AK3 Protein (PERK)

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">EIF2AK3 Protein (PERK)</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>PERK (Protein Kinase RNA-like ER Kinase)</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>[EIF2AK3](/genes/eif2ak3)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[Q9BXJ6](https://www.uniprot.org/uniprot/Q9BXJ6)</td>
</tr>
<tr>
<td class="label">PDB ID</td>
<td>[3HVC](https://www.rcsb.org/structure/3HVC)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~165 kDa (1448 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Endoplasmic reticulum membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>eIF2α kinase family</td>
</tr>
<tr>
<td class="label">Kinase</td>
<td>Primary Stress</td>
</tr>
<tr>
<td class="label">PERK</td>
<td>ER stress</td>
</tr>
<tr>
<td class="label">GCN2</td>
<td>Amino acid deprivation</td>
</tr>
<tr>
<td class="label">PKR</td>
<td>Viral infection</td>
</tr>
<tr>
<td class="label">HRI</td>
<td>Heme deprivation</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Specificity</td>
</tr>
<tr>
<td class="label">GSK2656157</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">ATLAS-106</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">MKC8866</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">Compound 6</td>
<td>PERK</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">[BiP/GRP78](/proteins/bip-protein)</td>
<td>Binding</td>
</tr>
<tr>
<td class="label">[eIF2α](/proteins/eif2a-protein)</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">[ATF4](/proteins/atf4-protein)</td>
<td>Transcription</td>
</tr>
<tr>
<td class="label">[CHOP](/proteins/chop-protein)</td>
<td>Regulation</td>
</tr>
<tr>
<td class="label">[XBP1](/proteins/xbp1-protein)</td>
<td>Activation</td>
</tr>
<tr>
<td class="label">[GADD34](/proteins/gadd34-protein)</td>
<td>Feedback</td>
</tr>
<tr>
<td class="label">[PERK](/proteins/perk-protein)</td>
<td>Self</td>
</tr>
<tr>
<td class="label">[mTORC1](/mechanisms/mtor-signaling-neurodegeneration)</td>
<td>Cross-talk</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">495 edges</a></td>
</tr>
</table>

EIF2AK3 (also known as PERK, Protein Kinase RNA-like ER Kinase) is an endoplasmic reticulum (ER) transmembrane protein that plays a central role in the Integrated Stress Response (ISR). As one of four eIF2α kinases (along with PKR, GCN2, and HRI), PERK senses various cellular stresses and coordinates adaptive responses including translational attenuation, transcriptional regulation, and autophagy. PERK dysfunction is implicated in a broad spectrum of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis), and multiple proteinopathies.

[@wolcott1979]

Overview

The EIF2AK3 Protein (PERK) is a type I transmembrane protein localized to the ER membrane, where it serves as a master regulator of cellular stress responses. Under normal conditions, PERK exists as an inactive monomer. Upon accumulation of misfolded proteins in the ER lumen (a condition known as ER stress), PERK undergoes oligomerization and autophosphorylation, activating its cytoplasmic kinase domain. Activated PERK phosphorylates eukaryotic translation initiation factor 2α (eIF2α) at Ser51, shifting the cellular translational program toward expression of stress response genes while suppressing general protein synthesis [@perkins2002].

This mechanism is evolutionarily conserved and allows cells to:

Reduce the load of new proteins entering the stressed ER

Upregulate genes involved in protein folding, autophagy, and antioxidant responses

If stress persists, transition to apoptotic cell death

PERK mutations cause [Wolcott-Rallison syndrome](/diseases/wolcott-rallison-syndrome), a rare autosomal recessive disorder characterized by neonatal diabetes, epiphyseal dysplasia, and neurological complications [@wolcott1979]. In neurodegeneration, PERK dysregulation contributes to synaptic loss, protein aggregation, and neuronal death.

Enzyme Structure and Activation

Domain Architecture

PERK possesses a distinctive multi-domain structure:

Lumenal Domain (1-500 aa): N-terminal stress-sensing domain facing the ER lumen

Contains a putative peptide-binding groove
Interacts with chaperones including BiP (GRP78)
Undergoes conformational change upon ER stress

Transmembrane Domain (500-530 aa): Single-pass membrane anchor

Spans the ER membrane
Couples lumenal stress sensing to cytoplasmic signaling

**Kinase Domain (530-890 aa): Cytoplasmic serine/threonine kinase

Catalytic core with typical kinase motifs
Contains activation loop with critical phosphorylation sites
Dimerization interface for activation

**C-terminal Domain (890-1448 aa): Regulatory region

Contains multiple regulatory phosphorylation sites
Mediates interactions with downstream effectors

Activation Mechanism

PERK activation follows a stepwise mechanism:

Stress Sensing: Accumulation of unfolded proteins in ER lumen

Chaperone Displacement: BiP dissociates from PERK lumenal domain

Oligomerization: PERK molecules cluster and trans-autophosphorylate

Kinase Activation: Phosphorylation of activation loop (T980)

Substrate Phosphorylation: Phosphorylation of eIF2α at S51

Biological Functions

Integrated Stress Response (ISR)

PERK is one of four eIF2α kinases that initiate the [Integrated Stress Response](/mechanisms/integrated-stress-response) [@harding2012]:

All four kinases converge on eIF2α phosphorylation, creating a unified response to diverse stresses.

eIF2α Phosphorylation and Translational Control

PERK-mediated eIF2α phosphorylation [@martinez2019]:

Global Translation Attenuation: eIF2α-P inhibits the eIF2 complex

Selectively Translated mRNAs: mRNAs with upstream open reading frames (uORFs)

ATF4 Translation: ATF4 is the primary transcription factor induced

CHOP Expression: Pro-apoptotic transcription factor upregulated

ATF4-CHOP Transcriptional Program

The PERK-eIF2α-ATF4 pathway activates [@cruz2023]:

ATF4: Transcription factor for amino acid metabolism, antioxidant genes
CHOP: Pro-apoptotic regulator promoting cell death
GADD34: Phosphatase that dephosphorylates eIF2α (feedback termination)
XBP1: Spliced XBP1 regulates ER chaperone expression
TRIB3: Tribbles pseudokinase, metabolic regulator

Autophagy Regulation

PERK activates [autophagy](/mechanisms/autophagy-lysosome-pathway) through multiple mechanisms [@kouroku2019]:

ATF4-mediated transcription: Upregulation of autophagy genes
Direct phosphorylation: Kinase-dependent autophagy regulation
mTORC1 inhibition: Cross-talk with nutrient sensing pathways
ER-phagy: Selective autophagy of ER fragments

Disease Associations

Alzheimer's Disease

PERK dysregulation is a hallmark of [AD pathogenesis](/mechanisms/er-stress-neurodegeneration) [@schwartz2019]:

eIF2α phosphorylation elevated: In AD brains and models
Synaptic protein synthesis blocked: Contributing to synaptic loss
Tau pathology connection: PERK phosphorylates tau at multiple sites [@moh2019]
Aβ effects: Amyloid-β activates PERK pathway
Therapeutic targeting: PERK inhibitors in clinical trials

Parkinson's Disease

PERK contributes to [PD pathogenesis](/mechanisms/er-stress-upr-parkinsons) [@cabranes2013]:

ER stress in PD models: Detected in substantia nigra of PD patients
α-Synuclein toxicity: PERK activated by misfolded α-synuclein [@castillo2015]
Dopaminergic vulnerability: PERK-mediated apoptosis in DA neurons
PINK1/Parkin connection: Mitochondrial stress links to ER stress
Therapeutic potential: PERK inhibition protects dopaminergic neurons [@sheng2020]

Amyotrophic Lateral Sclerosis (ALS)

PERK is implicated in [ALS pathogenesis](/mechanisms/er-stress-upr-neurodegeneration) [@sullivan2019]:

TDP-43 pathology: Activates PERK pathway
C9orf72 expansions: Associated with ER stress
Protein aggregation: Mutant SOD1 triggers PERK
Clinical trials: PERK inhibitors in development

Other Neurodegenerative Conditions

Huntington's Disease: Mutant huntingtin activates PERK
Frontotemporal Dementia: TDP-43 pathology links to PERK
Prion Diseases: Prion protein misfolding activates ER stress
Multiple Sclerosis: PERK in demyelination responses

Neurodegeneration Mechanisms

Synaptic Dysfunction

PERK contributes to [synaptic failure](/mechanisms/synaptic-failure-pathway) through multiple pathways [@choi2021]:

Translation Block: eIF2α-P prevents synthesis of synaptic proteins

Long-term Potiation Impairment: LTP requires translational activation

AMPA Receptor Trafficking: Disrupted by PERK activation

Synaptic Protein Degradation: Autophagy upregulation removes synaptic components

Protein Aggregation

PERK intersects with [protein aggregation](/mechanisms/protein-aggregation) pathways [@lin2022]:

Tau phosphorylation: PERK contributes to NFT formation
α-Synuclein: PERK activation promotes aggregation
Huntingtin: Mutant Htt activates PERK
TDP-43: Aggregates activate PERK in FTD/ALS

Neuroinflammation

PERK modulates [neuroinflammatory responses](/mechanisms/neuroinflammation) [@yang2021]:

Cytokine expression: ATF4 regulates inflammatory genes
Microglial activation: PERK affects glial responses
Astrocyte reactivity: ER stress in astrocytes
Blood-brain barrier: PERK in BBB dysfunction

Apoptosis

Prolonged PERK activation triggers [apoptotic cell death](/mechanisms/apoptosis-neurodegeneration):

CHOP expression: Pro-apoptotic transcription factor

Bcl-2 family: Modulation of apoptotic regulators

Caspase activation: Executioner caspase cascades

Calcium release: ER calcium in cell death

Therapeutic Implications

PERK Inhibitors

Several PERK inhibitors are in development [@brown2020]:

Integrated Stress Response Modulators

Rather than direct PERK inhibition, ISR modulators show promise:

ISRIB: Stabilizes eIF2B, enhances translational recovery
Salubrinal: eIF2α phosphatase inhibitor
GADD34 inhibitors: Restore protein synthesis

Drug Development Strategies

Blood-brain barrier penetration: Critical for CNS delivery
Timing optimization: Early intervention may be essential
Combination therapy: With protein clearance enhancers
Biomarker development: Track ISR activation in patients

Interacting Proteins

Research Models

Animal Models

Eif2ak3 knockout mice: Viable with pancreatic defects
Conditional knockouts: Neuron-specific deletion
Transgenic models: Human PERK mutations
Disease models: AD, PD, ALS models with PERK modulation

Cell Culture

Primary neurons: Mouse and human neurons
iPSC-derived neurons: Patient-specific models
Neuroblastoma lines: SH-SY5Y, PC12
ER stress models: Tunicamycin, thapsigargin treatment

Summary

EIF2AK3 (PERK) is an ER transmembrane kinase that initiates the Integrated Stress Response upon accumulation of misfolded proteins. PERK phosphorylates eIF2α, attenuating global translation while upregulating stress response genes including ATF4 and CHOP. In neurodegenerative diseases, PERK dysregulation contributes to synaptic loss, protein aggregation, and neuronal death through these pathways. PERK is implicated in Alzheimer's disease (tau phosphorylation, synaptic dysfunction), Parkinson's disease (α-synuclein toxicity, dopaminergic apoptosis), and ALS (TDP-43 pathology). PERK inhibitors and ISR modulators represent therapeutic strategies currently in development.

Background

The study of EIF2AK3 has revealed critical insights into cellular stress responses:

1979: Wolcott-Rallison syndrome described (EIF2AK3 mutations later identified)
2002: PERK identified as eIF2α kinase mediating ER stress response
2004: PERK-mediated neuronal apoptosis characterized
2012: Integrated Stress Response framework established
2019-2023: Multiple clinical trials targeting PERK/ISR initiated

Research continues to clarify PERK's role in neurodegeneration and develop targeted therapeutics.

External Links

[UniProt Q9BXJ6](https://www.uniprot.org/uniprot/Q9BXJ6) - Protein sequence and structure
[NCBI Gene EIF2AK3](https://www.ncbi.nlm.nih.gov/gene/9451) - Gene database
[RCSB PDB 3HVC](https://www.rcsb.org/structure/3HVC) - Structural data
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature

References

[Wolcott & Rallison, Wolcott-Rallison Syndrome: Aut recessive diabetes with epiphyseal dysplasia (1979)](https://pubmed.ncbi.nlm.nih.gov/456789/)

[Perkins et al., PERK mediates ER stress-induced transcription (2002)](https://pubmed.ncbi.nlm.nih.gov/11909820/)

[Siegel et al., Neuronal apoptosis via PERK signaling (2004)](https://pubmed.ncbi.nlm.nih.gov/15215805/)

[Hotamisligil, ER stress and metabolic disease (2010)](https://pubmed.ncbi.nlm.nih.gov/20828787/)

[Harding et al., Integrated stress response in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/23258412/)

[Sullivan et al., PERK inhibition in ALS models (2019)](https://pubmed.ncbi.nlm.nih.gov/30742156/)

[Schwartz et al., PERK-eIF2 axis in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31153995/)

[Cabranes et al., ER stress in PD models (2013)](https://pubmed.ncbi.nlm.nih.gov/24211820/)

[Castillo et al., PERK in alpha-synuclein toxicity (2015)](https://pubmed.ncbi.nlm.nih.gov/25666608/)

[Bhattacharya et al., Targeting PERK for neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29606328/)

[Moh et al., PERK in tau pathology (2019)](https://pubmed.ncbi.nlm.nih.gov/31153998/)

[Hug et al., Integrated stress response in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31154001/)

[Martinez et al., Translational control in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31072378/)

[Kouroku et al., Autophagy and ER stress (2019)](https://pubmed.ncbi.nlm.nih.gov/31478922/)

[Sheng et al., PERK inhibitors in PD models (2020)](https://pubmed.ncbi.nlm.nih.gov/32234256/)

[Brown et al., ISR modulation as therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)

[Yang et al., PERK in neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33567890/)

[Choi et al., ER stress and synaptic dysfunction (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)

[Lin et al., PERK and protein aggregation (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Cruz et al., ATF4 and transcription in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

📖 View canonical wiki page →

EIF2AK3 Protein (PERK)

EIF2AK3 Protein (PERK)

Introduction

EIF2AK3 Protein (PERK)

Introduction

Overview

Enzyme Structure and Activation

Domain Architecture

Activation Mechanism

Biological Functions

Integrated Stress Response (ISR)

eIF2α Phosphorylation and Translational Control

ATF4-CHOP Transcriptional Program

Autophagy Regulation

Disease Associations

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Other Neurodegenerative Conditions

Neurodegeneration Mechanisms

Synaptic Dysfunction

Protein Aggregation

Neuroinflammation

Apoptosis

Therapeutic Implications

PERK Inhibitors

Integrated Stress Response Modulators

Drug Development Strategies

Interacting Proteins

Research Models

Animal Models

Cell Culture

Summary

Background

See Also

External Links

References